Bio-Rad launches four new droplet digital PCR platforms

Bio-Rad Laboratories has significantly expanded its droplet digital PCR (ddPCR) capabilities with the launch of four new platforms, combining internal development with strategic acquisition expertise. The company’s enhanced portfolio now delivers the most comprehensive digital PCR solutions available for life science research and diagnostic applications.

The newly introduced instruments include Bio-Rad’s proprietary QX Continuum ddPCR system alongside the QX700 series of ddPCR platforms, acquired through the company’s recent completion of its Stilla Technologies acquisition. This expansion builds upon Bio-Rad’s established QX200 and QX600 ddPCR systems, creating an integrated portfolio spanning over 400,000 assays.

Advanced multiplexing capabilities drive workflow simplification

The QX Continuum ddPCR system targets translational research applications with distinctive design features. This all-in-one configuration delivers qPCR-like workflow simplicity whilst maintaining performance and flexibility. The platform enables four-colour multiplexing capabilities and supports up to eight discrete thermal profiles per plate, addressing complex experimental requirements.

“With this launch, our expanded portfolio of instruments, reagents, software, and services extends Bio-Rad’s presence in the genomics research and applied science markets and strengthens our leadership in droplet digital PCR solutions,” said Jim Barry, executive vice president and president of Bio-Rad’s Life Science Group.

QX700 series delivers enhanced throughput for diverse applications

The QX700 series comprises three new ddPCR instruments specifically engineered for academic research, environmental testing, cell and gene therapy, and biopharmaceutical quality control workflows. These systems feature seven-colour multiplexing capabilities and can process over 700 samples per day with minimal input volume requirements.

The platforms incorporate continuous loading capability and streamlined software interfaces for simplified data interpretation, addressing critical workflow bottlenecks in high-throughput laboratory environments. This enhanced capacity supports diverse applications including oncology, infectious disease research, and genetic analysis.

Strategic acquisition strengthens digital PCR leadership

Barry emphasised the strategic importance of the expanded portfolio: “The newly introduced platforms complement Bio-Rad’s existing QX ddPCR portfolio and offer our customers unparalleled workflow simplicity and throughput capabilities across the full spectrum of digital PCR applications including oncology, infectious disease, and genetic research.”

The integration of Stilla Technologies’ digital PCR development expertise demonstrates Bio-Rad’s commitment to advancing absolute quantification, high precision measurement, and advanced multiplexing capabilities. The end-to-end solutions feature industry-leading performance combined with streamlined workflows designed to enhance laboratory productivity.

Market positioning and clinical impact

Bio-Rad’s comprehensive digital PCR portfolio addresses growing demand for precise molecular quantification across clinical diagnostics and research applications. The enhanced multiplexing capabilities and increased throughput directly support expanding requirements in precision medicine, therapeutic monitoring, and genomic research programmes.